[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Pakistan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":690},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,1227,0,25,[9,52,83,111,140,173,202,221,250,282,315,342,369,399,421,442,475,494,519,544,570,602,625,644,667],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100613303","this-clinical-trial-aims-to-compare-the-effectiveness-of-two-intra-pulpal-cryotherapy-techniques-endo-ice-and-ice-sticks-in-decreasing-intra-operative-pain-and-enhancing-the-success-of-local-anesthesia-during-pulpectomy-of-mandibular-molars-with-symptomatic-irreversible-pulpitis-100613303",false,"NCT07264829","This Clinical Trial Aims to Compare the Effectiveness of Two Intra-pulpal Cryotherapy Techniques-Endo-ice and Ice Sticks-in Decreasing Intra-operative Pain and Enhancing the Success of Local Anesthesia During Pulpectomy of Mandibular Molars With Symptomatic Irreversible Pulpitis.","Comparative Analysis of Intra-pulpal Cryotherapy Methods During Pulpectomy in Molars With Symptomatic Irreversible Pulpitis: A Randomized Control Trial","Inclusion Criteria:\n\n1. Individuals (Male and Female) aged 18 to 40 years.\n2. Healthy individuals with no significant present and past medical findings.\n3. Mandibular molars.\n4. Symptomatic irreversible pulpitis (moderate to severe pain according to VAS 4-10).\n5. Periapical index (PAI) Score: 1-3 on periapical radiograph.\n6. DAS-R: 4-14( mild to moderate anxiety)\n\nExclusion Criteria:\n\n1. Immature teeth with open apices.\n2. Calcified pulp chamber and canals.\n3. Periodontally compromised teeth.\n4. Individuals who had taken steroids, analgesics, or antibiotics within the last 48 hours.","ALL","18 Years","40 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trail is to compare the analgesic effect of endo-ice and ice-sticks in reducing intra-operative pain during pulpectomy in molars with Symptomatic Irreversible Pulpitis. Principal Investigator will perform the procedure and outcome assessor will interview the participants as well as fill the pre-operative questionnaire. The patient will be instructed beforehand on how to score their pre-operative, intra-operative and post-operative intensity of pain according to Visual Analogue Scale.The Anxiety level of patient will also be recorded according to the Corah's Dental Anxiety Scale questionnaire and their level of anxiety before and after the intervention will be recorded by the outcome assessor.\n\nThe principal investigator will perform all endodontic procedures, with the outcome assessor blinded to the cryotherapy method. Prior to administering IANB, a topical anesthetic gel will be applied. A 27-gauge needle will deliver 1.8 ml of 2% lidocaine with 1:100,000 epinephrine at a rate of 1 ml\u002Fmin. After a 5-minute wait, anesthesia effectiveness will be confirmed through electric pulp testing (EPT) on a neighboring tooth, with two consecutive negative responses confirming success. Once adequate anesthesia is confirmed, an access opening will be made under rubber dam isolation for the procedure.\n\n1. CONTROL GROUP: After access opening and complete de-roofing of the pulp chamber, pulpectomy of the inflamed pulp will be performed under the given effective IANB with no additional intervention to control intra-operative pain.\n2. ENDO-ICE GROUP: After access opening, pulp will be exposed and de-roofing will be performed. Endo-ice with the help of cotton pellet will be applied inside the pulp chamber for 2min (8 consecutive applications, 15sec each) and pulpectomy of the inflammed pulp will be performed immediately.\n3. ICE-STICKS GROUP: Following the access opening and complete de-roofing of pulp chamber, four ice sticks will be placed inside the pulp chamber for 2 minutes (30 seconds each, using tweezer). Subsequently, pulpectomy of the inflamed pulp will be performed immediately.\n\nPatients will be asked to rate their level of pain to the outcome assessor at four specific intervals during the trial, i.e., pre-operative (before local anesthesia), pre-operative (after local anesthesia), during pulpectomy and immediately after pulp extirpation and it will be recorded in a proforma by the blinded outcome assessor.\n\nPain and Anxiety Scores will be compared to asses either cryotherapy or which method of cryotherapy found to be effective in reducing intra-operative pain.",[28,29,30,31],"Root Canal Treatment","Intra-operative Pain","Symptomatic Irreversible Pulpitis","Cryotherapy Effect",[33,34,35,36,37,38,30],"Cryotherapy","Endodontic treatment","Intra-operative pain","Pulpectomy","Endo-ice","Ice-sticks","NOT_YET_RECRUITING","2026-08-24",{"date":42,"type":43},"2026-08-25","ACTUAL",{"date":45,"type":22},"2026-09-15",{"date":47,"type":22},"2026-12-30",{"name":49,"class":50},"Dow University of Health Sciences","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":7},"100579387","an-international-multicenter-study-on-transcatheter-device-closure-of-perimembranous-ventricular-septal-defects-100579387","NCT06823635","An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects","PERI-CLOSE","Inclusion Criteria:\n\n1. Patients with perimembranous ventricular septal defects (PmVSD) diagnosed by 2D transthoracic echocardiography according to established classification systems, who provided informed consent and underwent transcatheter closure using any commercially available occluder devices (whether specifically designed for this indication or used off-label), with follow-up according to local hospital protocols.\n2. Defect size between 3 mm and \\\u003C20 mm on the left ventricular side, as measured by 2D echocardiography.\n3. Age ≥1 month and body weight ≥5 kg.\n4. Left-to-right ventricular shunt.\n\nExclusion Criteria:\n\n1. Patients or legal guardians refusing the use of personal data for research purposes.\n2. Failure to attend any follow-up visit post-discharge.","1 Month",{"count":61,"type":22},2000,"OBSERVATIONAL","The international multicenter registry aims to gather real-world data on patient outcomes and assess the procedural success and performance of various device occluders used in the transcatheter treatment of pediatric and adult patients with perimembranous ventricular septal defects (PmVSD).",[65],"Perimembranous Ventricular Septal Defect",[67,68,69,70,71,72,73,74],"Cardiovascular Abnormalities","Congenital Heart Disease","Device Closure","Heart Defects, Congenital","Heart Septal Defects","Heart Septal Defects, Ventricular","Transcatheter Interventions","Ventricular Septal Defects","RECRUITING",{"date":42,"type":43},{"date":78,"type":43},"2025-01-01",{"date":80,"type":22},"2027-06-30",{"name":82,"class":50},"Fondation Hôpital Saint-Joseph",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":51},"100653293","effectiveness-of-oral-nicotine-pouches-as-a-cessation-tool-among-adult-tobacco-users-in-pakistan-100653293","NCT07785479","Effectiveness of Oral Nicotine Pouches as a Cessation Tool Among Adult Tobacco Users in Pakistan","A Randomized Controlled Trial to Assess the Effectiveness of Oral Nicotine Pouches as a Cessation Tool Among Adult Tobacco Users in Pakistan","Inclusion Criteria:\n\n* Adult smokers aged 18 to 65 years.\n* Currently smoke 10 to 14 cigarettes per day.\n* Express a willingness to quit smoking.\n* Have no prior experience using oral nicotine pouches.\n* Have no contraindications to nicotine use.\n* Able and willing to provide written informed consent.\n* Able and willing to comply with all study procedures and follow-up assessments.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Individuals with severe cardiovascular disease or other conditions that make nicotine use unsafe.\n* Participants currently enrolled in another smoking cessation program or clinical trial.\n* Individuals with known allergy or hypersensitivity to nicotine or any component of the oral nicotine pouches.\n* Individuals with a history of significant psychiatric disorders that may interfere with study participation.\n* Individuals unable or unwilling to comply with study procedures or follow-up visits.","65 Years",{"count":92,"type":22},148,[25],"Smoking remains a major public health challenge in Pakistan, where many adult smokers have limited access to effective smoking cessation support. This randomized controlled trial aims to evaluate whether combining oral nicotine pouches (Velo® 6 mg) with structured motivational counselling is more effective than motivational counselling alone in helping adult smokers quit smoking.\n\nThe study will enroll 148 adult smokers who smoke 10-14 cigarettes per day. Participants will be randomly assigned to one of two groups. One group will receive oral nicotine pouches together with motivational counselling, while the other group will receive motivational counselling only. The intervention will last for 12 weeks.\n\nThe main questions this study aims to answer are:\n\nDoes the combination of oral nicotine pouches and motivational counselling increase smoking cessation rates compared with motivational counselling alone? Does the intervention reduce cigarette cravings, withdrawal symptoms and the number of cigarettes smoked? Is the use of oral nicotine pouches safe, acceptable and well tolerated among adult smokers in Pakistan? How satisfied are participants with the treatment, and how well do they adhere to the intervention?\n\nParticipants will:\n\nBe randomly assigned to receive either oral nicotine pouches plus motivational counselling or motivational counselling alone.\n\nAttend study visits at baseline and at weeks 2, 4, 8 and 12. Undergo carbon monoxide breath testing to verify smoking status. Complete questionnaires on cigarette cravings, withdrawal symptoms, treatment satisfaction and adherence.\n\nReport cigarette consumption and any side effects throughout the study.\n\nThe findings from this trial will provide evidence on the effectiveness, safety, and acceptability of oral nicotine pouches as a smoking cessation aid for adult tobacco users in Pakistan and may help inform future tobacco harm reduction and smoking cessation strategies.",[96,97],"Tobacco Cessation","Smoking Cessation",[99,100,97,96,101,102,103],"Oral Nicotine Pouches","Tobacco Harm Reduction","Motivational Counselling","Behavioral Counselling","Pakistan","2026-08-23",{"date":42,"type":43},{"date":107,"type":22},"2026-09-01",{"date":80,"type":22},{"name":110,"class":50},"Cyntax Health Projects PVT LTD",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100631351","phase-3-a-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-libevitug-in-participants-with-chronic-hdv-infection-d-clear-study-100631351","NCT07499544","A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)","A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)","Inclusion Criteria:\n\n* Willing to sign written informed consent;\n* Chronic HDV history with at least 6 months;\n* HDV RNA ≥500 IU\u002FmL at screening;\n* ALT \\>1ULN and \\\u003C10×ULN;\n* Able to communicate well and comply with protocol.\n\nExclusion Criteria:\n\n* Concomitant decompensated cirrhosis;\n* Previous or current HCC or suspicion for HCC;\n* Participants with history of alcoholic liver disease, nonalcoholic steatohepatitis or other clinically significant chronic liver diseases not caused by HDV\u002FHBV;\n* Participants with active hepatitis C infection, or HIV infection;\n* Alcohol abuse or drug addiction within 1 year;\n* Participants have participated in other clinical trial within 1 month;\n* Pregnant, lactating women.","12 Years","70 Years",{"count":121,"type":22},160,[123],"PHASE3","This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.",[126],"Chronic Hepatitis D Infection",[128,129],"Hepatitis Delta Virus (HDV)","Viral hepatitis","2026-08-21",{"date":40,"type":43},{"date":133,"type":43},"2026-04-22",{"date":135,"type":22},"2030-01-29",{"name":137,"class":138},"Huahui Health","INDUSTRY",7,{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":147,"minAge":18,"maxAge":19,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":157,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":171,"locationsCount":51},"100653207","effect-of-oxytocin-bolus-versus-slow-infusion-on-haemodynamic-stability-during-caesarean-section-under-spinal-anaesthesia-100653207","NCT07784478","Effect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia","Effect of Oxytocin Administration Technique on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Adult female patients aged 18 to 40 years\n* American Society of Anesthesiologists (ASA) physical status class I or II\n* Singleton pregnancy at 37 to 42 weeks gestational age\n* Scheduled for elective caesarean section under spinal anaesthesia\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Patients with anticipated hemodynamic instability including severe preeclampsia\u002Feclampsia, placenta previa with active bleeding, placental abruption, or hemorrhagic shock\n* Pre-existing cardiovascular disease including ischemic heart disease, valvular heart disease, cardiomyopathy, or arrhythmias\n* Baseline systolic blood pressure \\\u003C 100 mmHg or heart rate \\> 100 bpm before spinal block\n* Known hypersensitivity to oxytocin\n* Failed spinal anaesthesia requiring conversion to general anaesthesia\n* Patients receiving medications that may alter the hemodynamic response to oxytocin (beta-blockers, calcium channel blockers, ACE inhibitors, or angiotensin receptor blockers)\n* Pre-existing anaemia (Hb \\\u003C 8 g\u002FdL)","FEMALE",{"count":149,"type":22},60,[25],"This study compares two standard ways of giving oxytocin (a medicine that helps the uterus contract) after the baby is born during a planned caesarean section performed under spinal anaesthesia. One group of women will receive oxytocin as a quick injection into the vein. The other group will receive the same dose of oxytocin as a slow infusion over 15 minutes. The researchers want to find out which method causes less drop in blood pressure and other heart-related changes, while still providing good contraction of the uterus and preventing excessive bleeding.",[153,154,155,156],"Cesarean Section","Hypotension","Postpartum Hemorrhage","Spinal Anesthesia",[158,159,160,161,162,163,164,165],"Oxytocin","Bolus","Infusion","Haemodynamic stability","Elective caesarean section","Spinal anaesthesia","Uterine tone","Vasopressor","2026-08-20",{"date":42,"type":43},{"date":107,"type":22},{"date":170,"type":22},"2027-04-01",{"name":172,"class":50},"Khyber Girls Medical College",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":51},"100653202","effectiveness-of-saccharomyces-boulardii-in-prevention-of-antibiotic-associated-diarrhea-100653202","NCT07785206","Effectiveness of Saccharomyces Boulardii in Prevention of Antibiotic Associated Diarrhea","Effectiveness of Saccharomyces Boulardii in the Prevention of Antibiotic-Associated Diarrhea Among Children Receiving Co-amoxiclav for Upper Respiratory Tract Infection: A Randomized Control Trial","Inclusion Criteria:\n\n* Children aged 6 months to 5 years presenting with upper respiratory tract infection (URTI)\n* Prescribed standard oral co-amoxiclav therapy\n* Both male and female patients\n* Written informed consent provided by parents or legal guardians\n\nExclusion Criteria:\n\n* Presence of diarrhea at the time of study enrollment\n* Prior use of probiotics during the current course of illness\n* Receipt of any antibiotic other than co-amoxiclav within the 72 hours preceding enrollment\n* Concomitant use of other medications\n* Known allergy to co-amoxiclav or the probiotic Saccharomyces boulardii\n* Confirmed immunodeficiency disorder or current receipt of immunosuppressive therapy\n* History of chronic diarrhea\n* Presence of 3rd degree (severe) malnutrition\n* Presence of systemic symptoms or infections other than URTI (e.g., lower respiratory tract infection, jaundice)","6 Months","5 Years",{"count":183,"type":22},88,[25],"Antibiotic-associated diarrhea (AAD) is a common adverse effect in pediatric patients receiving broad-spectrum antibiotics such as co-amoxiclav for upper respiratory tract infections (URTI). This study aims to evaluate the effectiveness of the probiotic Saccharomyces boulardii in preventing antibiotic-associated diarrhea among children aged 6 months to 5 years receiving co-amoxiclav. Participants will be randomly allocated to receive either standard co-amoxiclav therapy alone or co-amoxiclav combined with Saccharomyces boulardii for 5 days. The primary objective is to evaluate whether the addition of Saccharomyces boulardii reduces the incidence of diarrhea during and up to 14 days following antibiotic therapy.",[187,188],"Antibiotic Associated Diarrhea","Upper Respiratory Tract Infection",[190,191,192,193,194],"Saccharomyces boulardii","Probiotics","Co-amoxiclav","Pediatrics","Diarrhea Prevention",{"date":42,"type":43},{"date":197,"type":22},"2026-09",{"date":199,"type":22},"2027-05",{"name":201,"class":50},"University of Child Health Sciences and Children's Hospital, Lahore",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":209,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":220,"locationsCount":51},"100651694","effect-of-citicoline-on-neurological-severity-score-and-cerebral-doppler-resistive-index-in-neonatal-hypoxic-ischemic-encephalopathy-a-randomized-control-trial-100651694","NCT07763145","Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy","Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control Trial","Inclusion Criteria:\n\n* All inborn neonates diagnosed with APGAR score (Table 2) less then 8\u002F10 at 5 min of life presenting to the emergency room within the first day of life.\n* Outborn babies admitted in the last 24 hours with history or clinical features of perinatal asphyxia.\n\nEXCLUSION CRITERIA :\n\n* Neonates who have received therapeutic hypothermia\n* Neonates with congenital, developmental or chromosomal malformations\n* Significant antenatal risk factors leading to early-onset sepsis\\\\DIC or CNS depression unrelated to asphyxia\n* Preterm neonates \\\u003C35 weeks\n* No consent could be obtained","0 Hours","24 Hours",{"count":212,"type":22},86,[25],"To determine the efficacy of citicoline in improving cerebral blood flow parameters and neurological status among neonates with hypoxic-ischemic encephalopathy using Doppler resistive index and Sarnat-Sarnat score after 72 hours of therapy.",[216],"Hypoxic Ischaemic Encephalopathy (HIE)",{"date":40,"type":43},{"date":107,"type":22},{"date":47,"type":22},{"name":172,"class":50},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":17,"minAge":228,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":237,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":51},"100651633","comparative-evaluation-of-immediate-vs-progressive-standing-dual-task-training-in-elderly-with-mild-and-moderate-cognitive-impairment-100651633","NCT07764250","Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive Impairment","Immediate Versus Progressive-Standing Dual-Task Training: A Comparative Evaluation in Elderly With Mild and Moderate Cognitive Impairment","Inclusion Criteria:\n\n* Age ≥55 years\n* Mild or moderate cognitive impairment\n* MoCA 10-25\n* MMSE 10-23\n* Able to participate\n* Provides informed consent\n\nExclusion Criteria:\n\n* Severe cognitive impairment\n* Severe sensory or musculoskeletal impairments\n* Unstable medical conditions\n* Participation in another intervention study","55 Years",{"count":230,"type":22},96,[25],"older adults with mild and moderate cognitive impairment. compare immediate vs progressive standing dual-task training. assess balance, cognition, executive function, mobility, and quality of life.",[234,235,236],"Cognitive Impairment","Cognitive Impairment, Mild","Moderate Cognitive Impairment",[238,239,240,241,242],"CI","MCI","DTT","ISDTT","PSDDT",{"date":40,"type":43},{"date":245,"type":43},"2026-06-25",{"date":247,"type":22},"2026-08-30",{"name":249,"class":50},"Shifa Tameer-e-Millat University",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":51},"100653377","gender-based-comparison-of-the-effects-of-sensory-modulated-graded-weight-bearing-physiotherapy-in-adults-with-knee-osteoarthritis-100653377","NCT07784998","Gender Based Comparison of the Effects of Sensory Modulated Graded Weight Bearing Physiotherapy In Adults With Knee Osteoarthritis","GSMGWBP","Inclusion criteria\n\n* Participants are eligible for inclusion if they meet the following criteria:\n* Age between 40 and 60 years.\n* Diagnosed with Grade II or Grade III Knee Osteoarthritis according to Kellgren-Lawrence Classification.\n* Ability to ambulate independently without assistive devices.\n* Mild to moderate pain intensity with a Visual Analogue Scale score less than seven.\n* Ability to understand and follow instructions.\n* Willingness to participate and provide written informed consent. Exclusion Criteria\n* Participants are excluded if they meet any of the following criteria:\n* History of knee surgery within the previous six months.\n* Neurological disorders affecting balance, gait, or proprioception.\n* Severe cardiovascular disease limiting participation in exercise.\n* Rheumatoid arthritis or other inflammatory arthritic conditions.\n* Severe cognitive impairment.\n* Any medical condition that contraindicates participation in rehabilitation exercises.","60 Years",{"count":259,"type":22},52,[25],"This comparative experimental study aims to evaluate the effectiveness of Sensory-Modulated Graded Weight-Bearing Physiotherapy (SMGWBP) in patients with knee osteoarthritis and compare treatment outcomes between male and female participants. Participants will receive a 6-week physiotherapy program with assessments conducted at baseline (pre-intervention), mid-intervention (3 weeks), and post-intervention (6 weeks) using validated outcome measures.",[263],"Knee Osteoarthristis",[265,266,267,268,269,270,271,272,273,274],"Knee Osteoarthritis","Sensory-Modulated Graded Weight-Bearing Physiotherapy","Physiotherapy","Rehabilitation","Pain","WOMAC","Proprioception","Six-Minute Walk Test","SF-36","Gender Differences","2026-08-19",{"date":42,"type":43},{"date":278,"type":43},"2026-07-13",{"date":280,"type":22},"2026-09-23",{"name":249,"class":50},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":289,"sex":17,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":51},"100653111","skin-staples-vs-polypropylene-in-elective-laparotomy-100653111","NCT07781878","Skin Staples vs Polypropylene in Elective Laparotomy","Skin Staples Versus Polypropylene for Skin Closure in Elective Laparotomy: A Randomized Controlled Trial","Inclusion Criteria:\n\nAge 15-50 years Elective laparotomy ASA I-III Written informed consent Male or female\n\nExclusion Criteria:\n\nEmergency surgery Previous SSI Recurrent surgery BMI \\\u003C18 or \\>30 kg\u002Fm² Haemoglobin \\\u003C10 g\u002FdL COPD Stroke Renal failure Liver disease Haematological disorders Malignancy Immunocompromised state Active infection Previous chemotherapy Previous radiotherapy Malnutrition",true,"15 Years","50 Years",{"count":293,"type":22},130,[25],"Surgical site infection (SSI) is one of the most common postoperative complications following elective laparotomy and contributes significantly to patient morbidity, prolonged hospital stay, and increased healthcare costs. Various techniques are available for skin closure, including skin staples and polypropylene sutures; however, evidence regarding their comparative effectiveness remains inconsistent, particularly in low- and middle-income countries.\n\nThis randomized controlled trial aims to compare skin staples with polypropylene sutures for skin closure following elective laparotomy. Eligible adult patients undergoing elective laparotomy at the Department of General Surgery, Pakistan Institute of Medical Sciences (PIMS), Islamabad, will be randomly allocated in a 1:1 ratio to receive either skin staples or polypropylene sutures.\n\nThe primary outcomes are skin closure time and incidence of surgical site infection within 30 days of surgery. Secondary outcomes include wound dehiscence, postoperative pain, cosmetic scar appearance, patient satisfaction, and duration of hospital stay.\n\nThe findings will provide evidence regarding the optimal skin closure technique for elective laparotomy in the Pakistani population.",[297],"Surgical Site Infection",[299,300,301,302,303,304,305,306],"Infection","SSI","SSIs","Laparatomy","Prolene suture","Staples","Wound Dehiscence","General surgery",{"date":40,"type":43},{"date":309,"type":43},"2026-01-31",{"date":311,"type":22},"2026-12-31",{"name":313,"class":314},"Pakistan Institute of Medical Sciences","OTHER_GOV",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":289,"sex":17,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":341,"locationsCount":51},"100652741","comparative-effects-of-integrated-versus-sequential-approaches-to-dual-task-training-in-elderly-with-mild-to-moderate-cognitive-impairment-a-four-arm-randomized-controlled-trial-100652741","NCT07775079","Comparative Effects of Integrated Versus Sequential Approaches to Dual-Task Training in Elderly With Mild to Moderate Cognitive Impairment","Comparative Effects of Integrated Versus Sequential Approaches to Dual-Task Training in Elderly With Mild to Moderate Cognitive Impairment: A Four-Arm Randomized Controlled Trial","nill","Inclusion Criteria:\n\n* Age \\> 55 years\n* MoCA: 10-25\n* MMSE: 10-23\n* Diagnosed cognitive impairment\n* Able to participate in training\n\nExclusion Criteria:\n\n* Severe cognitive impairment\n* Severe physical sensory limitations\n* Unstable medical conditions\n* Participation in other trials","55 Months","85 Months",{"count":230,"type":22},[25],"Mild and Moderate cognitive impairment is a condition characterized by a noticeable decline in cognitive abilities, including memory and thinking skills, which is greater than expected for an individual's age but does not significantly interfere with daily life. Early intervention is essential to prevent further cognitive decline and progression to dementia.\n\nDual-task training has emerged as an effective rehabilitation approach that combines cognitive and motor tasks to enhance neuroplasticity and improve both physical and cognitive performance. This study is designed to investigate the effectiveness of dual-task training compared to conventional therapy in individuals with mild cognitive impairment.\n\nParticipants meeting the inclusion criteria will be recruited and randomly allocated into intervention and control groups. The intervention group will receive structured dual-task training, which may include activities such as walking while performing cognitive tasks (e.g., counting, word recall), balance exercises combined with mental tasks, and functional activities requiring divided attention. The control group will receive standard rehabilitation or single-task training.\n\nThe intervention will be conducted over a specified duration (e.g., several weeks), with sessions held multiple times per week. Outcome measures will be assessed at baseline and after completion of the intervention. The primary outcome will be cognitive function measured using the Mini-Mental State Examination (MMSE). Secondary outcomes may include balance, mobility, and functional performance.\n\nData will be analyzed to determine the effectiveness of dual-task training in improving cognitive and functional outcomes. The results of this study may contribute to evidence-based rehabilitation practices and support the use of dual-task interventions in clinical settings.",[329,236],"Mild Cognitive Impairment (MCI)",[331,332,268,333,334,335,336,337],"Dual-task training","Cognitive Function","MMSE","MoCA","Balance training","Integrated training","Sequential training",{"date":130,"type":43},{"date":245,"type":43},{"date":247,"type":22},{"name":249,"class":50},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":147,"minAge":18,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":51},"100652896","phase-4-comparison-of-high--versus-low-dose-aspirin-for-pregnancy-outcomes-in-women-at-high-risk-of-preeclampsia-100652896","NCT07779057","Comparison of High- Versus Low-Dose Aspirin for Pregnancy Outcomes in Women at High Risk of Preeclampsia","High Versus Low Dose Aspirin Effects on Fetomaternal Outcomes in Women With High Risk of Preeclampsia","Inclusion Criteria:\n\n* Gestational age 11-14 weeks\n* High risk of preeclampsia\n\nExclusion Criteria:\n\n* Active gastritis\n* Abnormal coagulation profile (INR \\> 1.5)\n* Renal disease\n* Platelet count \\\u003C 150,000\u002Fmm\\^3\n* Fetal malformations\n* Vaginal bleeding","45 Years",{"count":149,"type":22},[352],"PHASE4","The goal of this randomized clinical trial is to compare the effects of two doses of aspirin, 75 mg and 150 mg, in pregnant women who are at high risk of developing preeclampsia.\n\nThe main question the study aims to answer is:\n\n1. Does taking 150 mg of aspirin reduce the occurrence of preeclampsia more effectively than taking 75 mg of aspirin in pregnant women at high risk of preeclampsia?\n2. Are there differences in stillbirth and newborn birth weight between the two aspirin doses?\n\nThe study will include 224 pregnant women aged 18-45 years who are between 11 and 14 weeks of pregnancy and are identified as being at high risk for preeclampsia. Participants will be randomly assigned to one of two groups.\n\n* Participants in the low-dose group will take 75 mg of aspirin once daily at bedtime.\n* Participants in the high-dose group will take 150 mg of aspirin once daily at bedtime.\n\nParticipants will continue their assigned aspirin dose until 36 weeks of pregnancy and will be followed every 2 weeks until delivery.\n\nThe study will record whether participants develop preeclampsia and whether stillbirth occurs. The birth weight of each newborn will also be measured within 3 hours of birth.\n\nThe study hypothesis is that 150 mg of aspirin will result in a lower incidence of preeclampsia than 75 mg of aspirin in pregnant women at high risk of preeclampsia.",[355],"Preeclampsia",[357,358,359,355,360],"Aspirin","Birth weight","Pregnancy","Stillbirth","2026-08-18",{"date":130,"type":43},{"date":364,"type":43},"2026-05-12",{"date":366,"type":22},"2026-11-11",{"name":368,"class":50},"Medicare Hospital (Pvt) Limited",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":291,"enrollmentInfo":377,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":381,"conditions":382,"keywords":385,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":51},"100652809","phase-2-topical-metformin-versus-triple-regimen-for-epidermal-melasma-100652809","NCT07779811","Topical Metformin Versus Triple Regimen for Epidermal Melasma","Comparison of Efficacy of Topical Triple Regimen Versus 30% Metformin in the Treatment of Epidermal Melasma","MET-MEL","Inclusion Criteria:\n\n* Male or female participants aged 18 to 50 years.\n* Confirmed diagnosis of epidermal melasma according to the study's operational definition.\n* Epidermal melasma confirmed by Wood's lamp examination, showing accentuated hyperpigmentation with enhanced contrast and sharp borders.\n* No treatment for epidermal melasma during the previous one month.\n* No dermabrasion, laser ablation, or chemical peel during the previous three months.\n* Willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Acne vulgaris.\n* Rosacea.\n* Pregnancy.\n* Presence of comorbid conditions.",{"count":378,"type":22},104,[380],"PHASE2","Melasma is a common skin condition that causes dark brown patches, mainly on sun-exposed areas of the face. It is often persistent, may recur after treatment, and can affect a person's quality of life. The standard topical triple regimen used for melasma contains hydroquinone, tretinoin, and fluocinolone acetonide. Although effective, prolonged use may cause adverse effects such as redness, burning, peeling, telangiectasia, and steroid-related skin changes. Topical metformin has recently been investigated as a possible alternative treatment because it may reduce skin pigmentation with relatively few side effects.\n\nThis randomized clinical trial will compare the efficacy of topical 30% metformin cream with a topical triple regimen in adults with epidermal melasma. A total of 104 participants aged 18-50 years will be enrolled, with 52 participants assigned to each treatment group. Group A will receive topical 30% metformin, while Group B will receive a triple regimen containing 2% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide. Participants will apply the assigned treatment once daily at night for eight consecutive weeks. All participants will also be advised to use SPF 50 or higher sunscreen in the morning.\n\nTreatment efficacy will be assessed by comparing the modified Melasma Area and Severity Index score at baseline and after eight weeks. Treatment will be considered effective when the participant achieves at least a 25% reduction in the modified MASI score from baseline. The findings may help identify a more effective and acceptable topical treatment option for patients with epidermal melasma",[383,384],"Epidermal Melasma","Facial Hyperpigmentation",[386,383,384,387,388,389,390,391],"Melasma","Topical Metformin","Triple Combination Therapy","Modified MASI","Randomized Clinical Trial","Topical Treatment",{"date":130,"type":43},{"date":394,"type":22},"2026-08-15",{"date":396,"type":22},"2027-01-30",{"name":398,"class":50},"Combined Military Hospital, Pakistan",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":291,"maxAge":119,"enrollmentInfo":406,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":419,"locationsCount":51},"100650887","effects-of-structural-integration-on-chest-wall-expansion-among-copd-patients-100650887","NCT07752420","Effects of Structural Integration on Chest Wall Expansion Among COPD Patients","Effects of \"The 10-Series of Structural Integration\" on Chest Wall Expansion Among COPD Patients","Inclusion Criteria:\n\n* Clinically diagnosed stable COPD according to GOLD criteria\n* GOLD stage II or III\n* No acute exacerbation within the previous four weeks\n* Able to ambulate independently\n* Medically cleared to participate in pulmonary rehabilitation\n* Willing to provide written informed consent\n\nExclusion Criteria:\n\n* Severe cardiovascular disease contraindicating exercise\n* Recent thoracic or abdominal surgery (\\\u003C6 months)\n* Rib fractures or severe chest wall deformity\n* Neurological disorders affecting mobility\n* Active malignancy\n* Severe osteoporosis with high fracture risk\n* Previous Structural Integration treatment within the last year",{"count":259,"type":22},[25],"The present study aims to investigate the effects of the 10-Series of Structural Integration on chest wall expansion in patients with stable COPD using a randomized controlled trial design. Participants receiving Structural Integration in addition to conventional pulmonary rehabilitation will be compared with those receiving conventional pulmonary rehabilitation alone. Chest wall expansion will serve as the primary outcome, while pulmonary function, dyspnea, functional exercise capacity, and quality of life may be evaluated as secondary outcomes.",[410],"COPD (With - Without Rehabilitation)",[412,413,414,415],"COPD","Structural Integration","Chest Wall Expansion","Pulmonary Rehabilitation",{"date":275,"type":43},{"date":107,"type":22},{"date":47,"type":22},{"name":420,"class":50},"Green International University",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":291,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":51},"100652722","magnesium-sulphate-with-atropine-and-pralidoxime-vs-standard-therapy-alone-in-acute-organophosphate-poisoning-100652722","NCT07777835","Magnesium Sulphate With Atropine and Pralidoxime vs Standard Therapy Alone in Acute Organophosphate Poisoning","Comparison of the Efficacy of Adjunctive Magnesium Sulphate With Standard Atropine and Pralidoxime Therapy vs Standard Therapy Alone in Acute Organophosphate Poisoning","Inclusion Criteria:\n\n* Both genders\n* Adult patients aged between 18 and 50 years\n* Confirmed clinical diagnosis of organophosphate poisoning containing insecticide, through the oral route\n* Adult patients, or their legally authorized representative, who will provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with known allergy to MgSO4\n* Patients with documented pre-existing renal impairment (Serum creatinine more than 1.5mg\u002Fdl)\n* Patients with documented pre-existing cardiac impairments (e.g., heart block)\n* Pregnant or lactating women\n* Confirmed intake of any other drug or poison\n* Patients who will be declared dead on arrival or those who expired within 2 hours of presentation",{"count":429,"type":22},38,[25],"Pakistan, being a developing country, is one of the regions with the most cases of organophosphate (OP) poisoning\u002Ftoxicity. MgSO4 is one of the most promising adjunctive treatments that needs to be tested. This study is being carried out with the objective of comparing the 15-day all-cause mortality rate and the total cumulative atropine requirement during hospitalization between patients receiving adjunctive magnesium sulphate with standard therapy and those receiving standard therapy alone.",[433],"Organophosphate Poisoning","2026-08-17",{"date":166,"type":43},{"date":437,"type":43},"2026-05-10",{"date":439,"type":22},"2026-10-10",{"name":441,"class":50},"Muhammad Aamir Latif",{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":290,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":51},"100652383","effect-of-alpha-binaural-beat-music-on-pain-after-orthodontic-separator-placement-100652383","NCT07771920","Effect of Alpha Binaural Beat Music on Pain After Orthodontic Separator Placement","The Effect of Alpha Binaural Beat Music on Orthodontic Pain After Placement of Orthodontic Separators: A Randomized Controlled Trial","ABB-PainRCT","Inclusion Criteria:\n\n* Patients aged 15-30 years.\n* Permanent dentition.\n* Mild crowding (≤3 mm arch length discrepancy).\n* Good periodontal health.\n* Requirement for fixed orthodontic treatment.\n* Requirement for bilateral maxillary first molar banding.\n* Requirement for placement of four elastomeric separators, consisting of one separator mesial and one separator distal to each maxillary first molar.\n* Ability to understand study instructions and complete study assessments.\n* Willingness to use stereo headphones.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Previous fixed orthodontic treatment.\n* Congenital or acquired hearing impairment.\n* Use of hearing aids or assistive listening devices.\n* History of tinnitus, hyperacusis, or sound sensitivity.\n* Active ear infection.\n* Recent upper respiratory tract infection associated with ear symptoms.\n* Neurological disorders.\n* Psychiatric disorders requiring treatment, including anxiety and depressive disorders.\n* Current use of analgesics, anti-inflammatory medications, antidepressants, anxiolytics, antipsychotics, or sedatives.\n* Chronic pain disorders.\n* Active periodontal disease or significant gingival inflammation.\n* Active dental pain, pulpal pathology, or oral infection.\n* Inability or unwillingness to use stereo headphones.\n* Inability to understand study instructions or complete study assessments.","30 Years",{"count":452,"type":22},72,[25],"Orthodontic pain is one of the most frequently reported adverse experiences during fixed appliance therapy and is particularly pronounced during the initial stages of treatment. Placement of orthodontic separators, a routine procedure performed to create interproximal space for orthodontic band placement, often causes discomfort that may negatively influence patient motivation, treatment acceptance, and overall orthodontic experience. Psychological factors, particularly anxiety, may also influence pain perception and contribute to individual differences in pain responses during orthodontic treatment. Therefore, interventions that address both pain and anxiety may improve patient comfort and adaptation to treatment.\n\nBinaural beats are auditory stimuli generated when two slightly different frequencies are presented separately to each ear, resulting in the perception of a third frequency equal to the difference between the two tones. Alpha-frequency binaural beats (8-13 Hz) have been associated with relaxation and reduced psychological arousal and have demonstrated promising analgesic and anxiolytic effects in various medical and dental settings. However, limited evidence exists regarding their role in the management of orthodontic pain following separator placement.\n\nThis prospective parallel-arm randomized controlled trial aims to evaluate the effect of alpha-frequency binaural beat stimulation on orthodontic pain and anxiety following separator placement. Seventy-two orthodontically treatment-naïve participants aged 15-30 years with permanent dentition, mild crowding (≤3 mm arch length discrepancy), good periodontal health, and a requirement for fixed orthodontic treatment will be recruited from the orthodontic clinics of Aga Khan University Hospital, Karachi, Pakistan. To minimize potential confounding factors and standardize the painful stimulus, all participants will require bilateral maxillary first molar banding and placement of four elastomeric separators, consisting of one separator mesial and one separator distal to each maxillary first molar. Participants will be randomly allocated in a 1:1 ratio to either an intervention group receiving alpha-frequency binaural beat stimulation or a control group undergoing a standardized five-minute resting period without auditory stimulation.\n\nThe binaural beat intervention consists of an 11-Hz alpha-frequency stimulus generated through the presentation of a 285-Hz carrier tone to one ear and a 296-Hz carrier tone to the other ear. Participants assigned to the intervention group will listen to a standardized pre-recorded audio file through stereo headphones for five minutes at designated assessment intervals. Orthodontic pain intensity will be assessed using the Visual Analogue Scale for Pain (VAS-P), anxiety levels will be measured using the Visual Analogue Scale for Anxiety (VAS-A), and analgesic consumption will be recorded during the observation period. Assessments will be conducted before separator placement, during separator placement, and at 6, 24, and 48 hours following the procedure.\n\nThe primary objective of this study is to evaluate the effect of alpha-frequency binaural beat stimulation on orthodontic pain intensity 24 hours after separator placement. Secondary objectives include evaluating pain intensity at 6 and 48 hours, anxiety levels, and analgesic consumption during the 48-hour observation period. The findings of this study will provide evidence regarding the effectiveness of alpha-frequency binaural beats as a simple, inexpensive, safe, and non-pharmacological adjunct for reducing orthodontic pain and anxiety and improving patient comfort during the early stages of orthodontic treatment.",[456,457],"Orthodontic Pain (D013850)","Anxiety",[459,460,461,462,463,457,464,465,466,467],"Orthodontics","Orthodontic Appliances","Orthodontic Pain","Pain Measurement","Acoustic Stimulation","Orthodontic Separators","Alpha Binaural Beats","Music Therapy","Nonpharmacological Pain Management",{"date":275,"type":43},{"date":470,"type":22},"2026-08-03",{"date":472,"type":22},"2026-09-18",{"name":474,"class":50},"Aga Khan University",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":481,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":51},"100652224","phase-2-evaluating-the-role-of-montelukast-in-management-of-acute-bronchiolitis-100652224","NCT07770464","Evaluating The Role Of Montelukast In Management Of Acute Bronchiolitis","Inclusion Criteria\n\n* Age 4 weeks to 2 years\n* Both genders\n* Duration of respiratory symptoms less than 4 days\n* Clinical diagnosis of acute bronchiolitis according to the operational definition provided in the study protocol\n\nExclusion Criteria\n\n* History of asthma\n* Previous hospital admissions for respiratory illness\n* Use of asthma medications\n* Congenital heart disease\n* Bronchopulmonary dysplasia\n* Immunodeficiency\n* Immunosuppression\n* Radiological evidence of pneumonia, including infiltrates or patches on chest X-ray","4 Weeks","2 Years",{"count":149,"type":22},[380],"This study aims to evaluate the role of Montelukast in management of acute Bronchiolitis in indoor patient and how this drug shortens the duration of admission and improves symptoms",[487],"Acute Bronchiolitis",{"date":361,"type":43},{"date":490,"type":43},"2026-01-01",{"date":492,"type":22},"2026-09-30",{"name":313,"class":314},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":17,"minAge":500,"maxAge":90,"enrollmentInfo":501,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":517,"locationsCount":51},"100652751","open-reduction-and-internal-fixation-of-humeral-midshaft-fracture-anterior-versus-posterior-plate-fixation-100652751","NCT07775690","Open Reduction and Internal Fixation of Humeral Midshaft Fracture: Anterior Versus Posterior Plate Fixation","Inclusion Criteria:\n\n* Presenting with humeral midshaft fracture (presence of fracture in the middle part or center of humerus )\n\nExclusion Criteria:\n\n* Patients with pathological or open fractures, concomitant fractures or ligament or tendon ruptures of elbow or shoulder joints (on clinical examination)\n* Patients presented after 14 days of injury, partial or complete disability of the elbow or shoulder joint on the affected side before injury\n* Previous surgical procedure on same side\n* Presence of neurovascular complications\n* Apparent dementia or other psychological problems","16 Years",{"count":502,"type":22},150,[25],"About 13 out of 10,000 patients get a humeral shaft fracture each year, accounting for 1.0-3.0% of all fractures. The central part of the humerus is where 60% of all humeral fractures occur. A midshaft humerus fracture typically happens because of a direct impact to the upper arm. Trauma, such as falls, motor vehicle accidents, or motorcycle accidents, is the most common cause of fractures. Internally fixing humeral shaft fractures is often accomplished by a variety of surgical techniques. Usually, the posterior technique is used to repair distal and mid-shaft fractures. However, the posterior technique necessitates lateral or prone stance. The aim of this study comparing the outcomes of internal fixation and open reduction of humeral midshaft fractures utilizing anterior and posterior plate fixation. We want to conduct this study to get evidence to confirm whether which approach is more appropriate and more successful in such fractures. Moreover, the findings of this research could profoundly influence clinical outcomes by guiding orthopedic surgeons in their decision-making for management of humeral midshaft fracture.",[506],"Humeral Shaft Fractures",[508,509,510,511],"Anterior plate fixation","Posterior plate fixation","Open reduction","Internal fixation","2026-08-16",{"date":166,"type":43},{"date":515,"type":43},"2026-02-17",{"date":434,"type":22},{"name":518,"class":50},"Dr Jahanzaib Ramay",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":525,"targetDuration":4,"studyType":23,"phases":527,"briefSummary":528,"conditions":529,"keywords":531,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":51},"100651822","role-of-n-acetylcysteine-in-non-acetaminophen-induced-liver-failure-100651822","NCT07765823","Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure","Inclusion Criteria:\n\n* Male or female, aged 18-60 years\n* Diagnosed with non-acetaminophen- induced acute hepatic failure (per operational definition\u002FEASL criteria)\n* Etiology other than acetaminophen overdose (viral hepatitis HAV\u002FHBV\u002FHEV, non-acetaminophen drug-induced liver injury, or idiopathic)\n* No NAC treatment received for current episode prior to enrollment\n\nExclusion Criteria:\n\n* History of chronic liver disease or cirrhosis\n* Prior severe cardiac, renal, neurological, or infectious disease that could confound outcomes\n* Prior liver transplant or current transplant candidacy\n* Known allergy\u002Fcontraindication to NAC\n* Pregnant women.",{"count":526,"type":22},62,[25],"This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival\u002Fmortality) and day 4 (liver function tests).",[530],"Acute Liver Failure",[532,533,534,535,536],"hepatic failure","acute liver failure","acetylcysteine","randomized controlled trial","supportive care",{"date":275,"type":43},{"date":539,"type":43},"2026-07-16",{"date":541,"type":22},"2026-10-17",{"name":543,"class":50},"King Edward Medical University",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":554,"briefSummary":555,"conditions":556,"keywords":559,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":568,"locationsCount":51},"100625641","integrated-oral-care-intervention-for-xerostomia-in-diabetes-patients-100625641","NCT07425275","Integrated Oral Care Intervention for Xerostomia in Diabetes Patients","The Impact of Integrated Oral Care Intervention Provided by Endocrinologists on Oral Health and Well-being in Diabetes Patients","IOCID","Inclusion Criteria:\n\n* Presence of a single stone in the renal pelvis.\n* Age less than 18 years.\n* No congenital or acquired urinary tract abnormalities.\n* No pre-existing chest diseases (e.g., chronic lung disease, pleural effusion).\n\nExclusion Criteria:\n\n* Patients with multiple kidney stones.\n* Calyceal stones (stones located specifically in a calyx).\n* Pelviureteric junction obstruction (PUJO).\n* Pelvic kidney (renal ectopia).",{"count":553,"type":22},80,[25],"Diabetes patients commonly experience dry mouth also known as xerostomia which can affect eating speaking oral health and overall quality of life. This study evaluates whether simple oral care actions delivered by endocrinologists during routine diabetes clinic visits can improve dry mouth symptoms and oral health related quality of life. Endocrinologists will be trained to screen for dry mouth provide brief counseling prescribe saliva substitutes and refer patients to dental services when needed. Adult patients with diabetes and symptoms of dry mouth will be followed before and after the intervention to assess changes in xerostomia severity and oral health outcomes. The study will also explore barriers and facilitators to integrating oral health care into routine diabetes management in Pakistan.",[557,558],"Diabetes Mellitus","Diabetic Neuropathies",[560,561,562,563],"Diabetes mellitus","Oral health quality of life","Non communicable diseases","Integrated oral care",{"date":361,"type":43},{"date":566,"type":43},"2026-08-01",{"date":396,"type":22},{"name":569,"class":50},"Khyber Medical University Peshawar",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":577,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":586,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":51},"100652531","effect-of-early-versus-late-premolar-extraction-on-orthodontic-tooth-movement-100652531","NCT07773389","Effect of Early Versus Late Premolar Extraction on Orthodontic Tooth Movement","Effect of Early vs Late Premolar Extraction on the Rate of Orthodontic Tooth Movement: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 13-25 years\n2. No prior orthodontic treatment\n3. Overjet 4-8 mm\n4. Symmetric dental arches with mild to moderate crowding requiring bilateral first premolar extractions.\n5. Probing depth less than 4 mm on all teeth\n\nExclusion Criteria:\n\n1. History of dental trauma\n2. Poor oral hygiene\n3. Syndromic patients\n4. Systemic diseases or medications affecting bone metabolism","13 Years","25 Years",{"count":580,"type":22},26,[25],"The goal of this randomized controlled trial is to evaluate whether the timing of premolar extraction affects the rate of orthodontic space closure during en-masse anterior retraction. The study will also assess gingival cleft formation, mesial movement of the upper first molars, ease and duration of premolar extraction, and patient-reported pain and anxiety.\n\nThe main question it aims to answer is:\n\nDoes early versus late premolar extraction affect the rate of orthodontic space closure?\n\nResearchers will compare two groups of patients. In the early extraction group the maxillary first premolars will be extracted before or within one week of start of fixed orthodontic treatment. In the late extraction group, the premolars will be extracted after alignment and immediately before the start of space closure.\n\nParticipants will:\n\n* Receive fixed orthodontic treatment and bilateral extraction of the maxillary first premolars.\n* Be randomly assigned to either the early-extraction or late-extraction group.\n* Undergo orthodontic alignment followed by en-masse anterior retraction.\n* Have dental impressions\u002Fdigital models obtained at the start of retraction and at 3 and 6 months to measure orthodontic tooth movement and space closure.\n* Be assessed for gingival clefts and mesial movement of the upper first molars.\n* Have the ease and duration of their premolar extraction recorded and report their pain and anxiety associated with the extraction procedure.",[584,585],"Malocclusion Class II","Malocclusion, Angle Class I",[587,588,589,590,591,592,593,594],"Orthodontic Tooth movement","Premolar extraction","Early Extraction","Late Extraction","Orthodontic Space Closure","En-masse anterior retraction","Gingival Cleft","Anchorage loss",{"date":275,"type":43},{"date":597,"type":43},"2026-07-22",{"date":599,"type":22},"2028-06",{"name":601,"class":50},"Shifa College of Dentistry",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":578,"maxAge":291,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":619,"startDateStruct":620,"completionDateStruct":621,"leadSponsor":623,"locationsCount":51},"100652442","comparison-of-functional-outcome-between-locking-plate-technique-versus-hybrid-ilizarov-technique-in-patients-with-schatzker-type-v-and-vi-tibial-plateau-fractures-100652442","NCT07773402","Comparison of Functional Outcome Between Locking Plate Technique Versus Hybrid Ilizarov Technique in Patients With Schatzker Type V and VI Tibial Plateau Fractures","TPF","Inclusion Criteria:\n\n* Patients of either sex.\n* Age between 25 and 50 years.\n* Patients presenting within 2 weeks of sustaining the fracture.\n* Patients diagnosed with complex tibial plateau fractures classified as Schatzker type V or VI.\n* Patients willing to participate in the study.\n* Patients providing written informed consent.\n\nExclusion Criteria:\n\n* Associated ipsilateral limb fractures.\n* Pathological fracture of the tibia.\n* Associated major organ injuries.\n* Psychiatric illness that may interfere with participation or outcome assessment.\n* Refusal to provide informed consent.",{"count":610,"type":22},78,[25],"This comparative clinical study will evaluate and compare the functional outcomes of patients with Schatzker type V and VI tibial plateau fractures treated using either the locking plate technique or the hybrid Ilizarov technique. Functional outcome will primarily be assessed using the Rasmussen Knee Functional Score. Fracture healing, time to union, non-union, delayed union, and infection will also be assessed and compared between the two treatment groups.",[614],"Tibial Plateau Fracture",[616,617,618],"Tibial plateau fracture","Schatzker type V","Schatzker type VI",{"date":275,"type":43},{"date":512,"type":22},{"date":622,"type":22},"2026-11-16",{"name":624,"class":50},"Prof. Sajjad Hussain Goraya",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":289,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":632,"targetDuration":4,"studyType":23,"phases":633,"briefSummary":635,"conditions":636,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":51},"100651428","early-phase-1-comparison-of-acetaminophen-nsaids-and-trypsin-chymotrypsin-plus-acetaminophen-for-post-endodontic-pain-after-single-visit-root-canal-treatment-100651428","NCT07759349","Comparison Of Acetaminophen, NSAIDs, And Trypsin-Chymotrypsin Plus Acetaminophen For Post-Endodontic Pain After Single-Visit Root Canal Treatment","Comparing the Effect of Acetaminophen, NSAIDs, Trypsin-chymotrypsin + Acetaminophen on Post-endodontic Pain Using Visual Analog Scale (VAS) After Single Visit Endodontic Treatment: A Randomized Controlled Trial","INCLUSION CRITERIA\n\n* Both sex\n* Healthy ( American Society of Anesthesiologists class 1)\n* Age 18-60 years\n* Pulpal diagnosis: Symptomatic irreversible pulpitis in mandibular premolar (single canal) periapical diagnosis: symptomatic apical periodontitis\n* The ability of participants to understand a pain scale (VAS)\n\nExclusion Criteria:\n\n* Pregnant females\n* Systemic disease and immune deficiency\n* Taken analgesics 24 hours, prior to treatment\n* Non-vital, previously initiated, previously treated teeth\n* Radiographic evidence of peri-radicular pathosis\n* Teeth with cracks, fractures and history of trauma\n* Developmental anomalies and immature apices\n* Allergic to local anesthetic solution or any experimental drugs\n* Patient being unable to provide informed consent.",{"count":21,"type":22},[634],"EARLY_PHASE1","This randomized control trial will be planned according to PRIRATE 2020 guideline for reporting randomized trials in Endodontics. The protocol of this study will be multiple parallel arm, single blinded, randomized single centered clinical trial (allocation ratio 1:1) The study will be conducted after taking the approval from the Institutional review board (IRB), Dow University of Health Sciences (Karachi). The participants will be selected according to the inclusion and exclusion criteria and on the basis of digital peri-apical radiograph and pulp sensibility test. After taking consent (Annexure form B) from patient, cold test will be performed by applying, a cotton pellet wetted with cold spray (Endodontia) to the middle third of the buccal surface of the affected tooth. Then results of electrical test will be assessed by using a digital electric pulp tester (EPT) \\[Parkell (Sybron Endo 91740)\\], applying the electrode to the buccal cusp on a location close to the pulp chamber of the premolar. VAS in written form will be provided to the patients and will explain the patient about the VAS reading and how to measure the pain intensity. Afterwards, endodontic treatment will be initiated by applying topical anesthetic gel (2% Benzocaine) along with local anesthesia (2% lidocaine with 1:100 000 epinephrine). Rubber dam isolation and access cavity preparation, working length will be determined by K-10 file (MANI) and confirmed both by apex locater (J.MORITA, Dentaport Zx) and with the help of digital periapical radiograph (DIGORA). After initial canal shaping and irrigation with sodium hypochlorite (5.25%), cleaning and shaping will be done by rotary Protaper gold file (Dentsply) in sequence SX, S1, S2, F1 ,F2 till F3. Canals will be dried by corresponding paper point and obturation will be done by lateral compaction. For the obturation Protaper gold gutta percha and accessory gutta percha (ISO) will be used with sealer (Sealapex). The orfices will be sealed and permanent restoration will be done by packable composite (Ivoclar). After performing endodontic treatment the respective drug inside the sealed envelope will be randomly given to the patient and the patient will be called at 6hrs, 12hrs, 24hrs, 48hrs and 72 hrs for the determination of pain intensity and that data will be entered in data entry form(Annexure form A).",[637],"Symptomatic Irreversible Pulpitis (SIP)",{"date":275,"type":43},{"date":640,"type":22},"2026-08-02",{"date":642,"type":22},"2026-12-01",{"name":49,"class":50},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":289,"sex":17,"minAge":650,"maxAge":500,"enrollmentInfo":651,"targetDuration":4,"studyType":23,"phases":653,"briefSummary":654,"conditions":655,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":51},"100652024","effectiveness-of-cognitive-behavioral-intervention-for-trauma-in-schools-cbits-a-study-with-pakistani-adolescents-100652024","NCT07768540","Effectiveness of Cognitive Behavioral Intervention for Trauma in Schools (CBITS): A Study With Pakistani Adolescents","Inclusion Criteria:\n\nStudents who are 10-16 years of age, have experienced at least one trauma.\n\nExclusion Criteria:\n\nStudents who have sexual abuse as only traumatic event","10 Years",{"count":652,"type":22},50,[25],"This study will evaluate whether a school-based counseling program, Cognitive Behavioral Intervention for Trauma in Schools (CBITS), helps reduce trauma-related symptoms and improve psychological functioning in adolescents in Pakistan who have experienced traumatic events. Students will first be screened to identify those with trauma exposure and related symptoms. Eligible students will receive the CBITS program, delivered at their school by the researcher. Researcher will measure changes in trauma-related symptoms and other psychological outcomes before and after the intervention to determine whether the program is effective for this population.",[656,657,658],"Post Traumatic Stress Symptoms","Psychological Distress","Trauma Exposure","2026-08-14",{"date":434,"type":43},{"date":662,"type":43},"2025-12-01",{"date":664,"type":22},"2027-02-28",{"name":666,"class":50},"National University of Modern Languages",{"id":668,"slug":669,"hasResults":12,"nctId":670,"briefTitle":671,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":17,"minAge":674,"maxAge":4,"enrollmentInfo":675,"targetDuration":4,"studyType":23,"phases":676,"briefSummary":677,"conditions":678,"keywords":680,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":682,"startDateStruct":683,"completionDateStruct":685,"leadSponsor":687,"locationsCount":689},"100599302","phase-3-a-study-to-evaluate-the-safety-and-efficacy-of-oral-nizubaglustat-az-3102-in-late-infantile-and-juvenile-forms-of-niemann-pick-type-c-disease-npc-100599302","NCT07082725","A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)","18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis","Inclusion Criteria:\n\n* Signed informed consent\n* Confirmed diagnosis of NPC disease\n* Patient is unable or unwilling to take miglustat, or is, in the opinion of the investigator, unsatisfactorily treated with miglustat\n* Male and female participants aged 4 years and older at the time of informed consent\n* Onset of neurological symptoms from 2 to 15 years\n* Disability level at Baseline: Ataxic disturbances with a total SARA score of ≥3 and ≤30 at Baseline\n* Female of childbearing potential who are sexually active willing to follow the contraceptive guidance\n* Male participants with a female partner of childbearing potential willing to follow the contraceptive guidance\n\nExclusion Criteria:\n\n* A history of medical conditions other than NPC disease that, in the opinion of the Principal Investigator, would confound scientific rigor or the interpretation of results\n* Body weight of \\\u003C10 kg\n* The presence of another neurologic disease\n* The presence of moderate or severe hepatic impairment\n* The presence of moderate or severe renal impairment\n* Platelet count of \\\u003C100x10\\^9\u002FL\n* The dose of any anti-epileptic treatment(s) was not stable (required a change in dose within the previous 3 months) and\u002For a new anti-epileptic treatment (drug or procedure) was prescribed in the month before Baseline\n* Prior use of an investigational drug within the 3 months before Screening; or prior participation in a clinical study involving gene therapy or stem cell transplantation within 2 years prior to Screening\n* A positive serum pregnancy test (for women of childbearing potential)\n* Current treatment with miglustat, provided the patient has been using the recommended dose for most of the past 12 months AND is, in the opinion of the investigator, satisfactorily treated with miglustat. Any participants receiving miglustat are required to undergo a 1-month washout period before starting study medication","4 Years",{"count":452,"type":22},[123],"An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease",[679],"Niemann-Pick Type C Disease",[681],"Nizubaglustat",{"date":434,"type":43},{"date":684,"type":43},"2025-06-30",{"date":686,"type":22},"2028-06-14",{"name":688,"class":138},"Azafaros B.V.",34,""]